Thrivent Financial for Lutherans Raises Holdings in Avanos Medical, Inc. $AVNS

Thrivent Financial for Lutherans boosted its stake in shares of Avanos Medical, Inc. (NYSE:AVNS) by 38.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 212,215 shares of the company’s stock after acquiring an additional 58,451 shares during the quarter. Thrivent Financial for Lutherans owned 0.46% of Avanos Medical worth $2,383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after acquiring an additional 2,307 shares during the period. Wexford Capital LP purchased a new stake in Avanos Medical during the 3rd quarter valued at about $70,000. Tower Research Capital LLC TRC boosted its holdings in Avanos Medical by 433.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after acquiring an additional 5,083 shares during the period. Quantessence Capital LLC purchased a new stake in Avanos Medical during the 3rd quarter valued at about $116,000. Finally, Virtu Financial LLC purchased a new stake in Avanos Medical during the 3rd quarter valued at about $136,000. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Wall Street Zen lowered Avanos Medical from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Zacks Research lowered Avanos Medical from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings raised Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Sell rating, According to MarketBeat, Avanos Medical currently has a consensus rating of “Sell”.

Avanos Medical Trading Up 0.1%

AVNS opened at $24.65 on Tuesday. The business has a 50 day simple moving average of $19.89 and a two-hundred day simple moving average of $15.13. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -15.31 and a beta of 1.58. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40. Avanos Medical, Inc. has a one year low of $9.30 and a one year high of $24.91.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.06. The business had revenue of $182.20 million during the quarter, compared to analyst estimates of $170.00 million. Avanos Medical had a positive return on equity of 5.39% and a negative net margin of 10.39%.Avanos Medical’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.26 EPS. Analysts predict that Avanos Medical, Inc. will post 1.07 EPS for the current year.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.